About HospiraNews & MediaInvestor RelationsIn the CommunitySearch :  
Home




In January 2004, USP Chapter <797>, "Pharmaceutical Compounding—Sterile Preparations", became the first official, enforceable requirement for the compounding of sterile preparations. The goal of USP <797> is to protect patients from the harm that can result from microbial contamination or medication errors in compounded sterile preparations.1,2

This section provides important and timely information to help pharmacists respond to USP <797>, and also discusses the important role that Hospira’s products can play in a pharmacy’s action plan.

Hospira is committed to partnering with healthcare professionals to develop innovative educational programs that enhance the practice of pharmacy.

About USP Chapter <797>
Products That Support Compliance Efforts
Information Request Form
CE Program: USP <797>
CE Program: An Update on USP Chapter <797>

References:

1. Kastango ES, Bradshaw BD. USP chapter 797: establishing a practice standard for compounding sterile preparations in pharmacy. Am J Health Syst Pharm. 2004;61:1928-1938.

2. USP General Chapter <797>. The current United States Pharmacopeia, 27th rev, and the National Formulary, 22nd ed, and Supplements. Rockville, Md: The United States Pharmacopeial Convention, 2004.

0
This Web site and its information is intended for use by United States residents only. Countries outside the United States may have regulatory requirements, data requirements or medical practices that differ from the United States and, therefore, this information may be inappropriate for use outside the United States. Site contents are intended for informational purposes only and not intended to replace discussion with a healthcare provider. If you have any questions regarding this site, contact Hospira.
9-084